🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ken Herrmann

Essen University Hospital

ORCID: 0000-0002-9662-7259

Also affiliated with University of Duisburg-Essen

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.6Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Cancers(2022)10.3390/cancers14071727

Top 13%

1.6DataRank

Top 13%47 citations

Julian Kirchner, Nils Martin Bruckmann, Janna Morawitz, Gerald Antoch, Saskia Ting +14 more

Papers

Driven by 13 papers — median percentile 87. Top paper: “Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer”.

Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Cancers(2022)10.3390/cancers14071727

Top 13%

1.6DataRank

Top 13%47 citations

Julian Kirchner, Nils Martin Bruckmann, Janna Morawitz, Gerald Antoch, Saskia Ting +14 more

Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.07.003

N/A

0.663DataRank · unranked

31 citations

K.N. Chi, Neal D. Shore, Ken Herrmann, Johann S. De Bono, Daniel Castellano +88 more

Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)

Journal of Nuclear Medicine(2021)10.2967/jnumed.121.262543

N/A

0DataRank · unranked

37 citations

Johannes Czernin, Pan Thin, J Gartmann, Kathleen Nguyen, Wesley R. Armstrong +14 more

Radiotheranostics in oncology: current challenges and emerging opportunities

Nature Reviews Clinical Oncology(2022)10.1038/s41571-022-00652-y

N/A

0DataRank · unranked

384 citations

Ken Herrmann, Heiko Schöder, Andrew M. Scott, Jason S. Lewis, Lisa Bodei

The Future of Targeted α-Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field

Journal of Nuclear Medicine(2022)10.2967/jnumed.122.264805

N/A

0DataRank · unranked

10 citations

Ken Herrmann, Lisa Bodei, Jonathan Strosberg

Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial

Journal of Nuclear Medicine(2020)10.2967/jnumed.120.242180

N/A

0DataRank · unranked

117 citations

Justin Ferdinandus, Johannes Czernin, Matthias Eiber, Robert R. Flavell, Spencer C. Behr +13 more

Radiotherapy and theranostics: a Lancet Oncology Commission

The Lancet Oncology(2024)10.1016/s1470-2045(24)00407-8

N/A

0DataRank · unranked

125 citations

Francesco Giammarile, M. Carrara, Diana Páez, Hedvig Hricak, Nayyereh Ayati +47 more

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102862

N/A

0DataRank · unranked

26 citations

Andrei Gafita, Johann S. De Bono, Oliver Sartor, Kim N., Bernd J. Krause +11 more

Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.01.30.577289

N/A

0DataRank · unranked

3 citations

Mohamed Altai, Katharina Lückerath, Wahed Zedan, Henan Zhu, Marija Trajkovic‐Arsic +25 more

Oncologist, Business Leader, and Investor Arie S. Belldegrun Discusses a Career in Innovative Medical Entrepreneurship

Journal of Nuclear Medicine(2024)10.2967/jnumed.124.268904

N/A

0DataRank · unranked

0 citations

Ken Herrmann, Johannes Czernin, Arie S. Belldegrun

Advances and challenges in precision imaging

The Lancet Oncology(2025)10.1016/s1470-2045(24)00395-4

N/A

0DataRank · unranked

44 citations

Marius E. Mayerhoefer, Ken Herrmann, Jason S. Lewis, Martin G. Pomper, Christopher P. Hess +4 more

Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response

Molecular Cancer Research(2023)10.1158/1541-7786.mcr-22-0736

N/A

0DataRank · unranked

3 citations

Mohamed Altai, Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian +14 more

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

The Lancet Oncology(2020)10.1016/s1470-2045(20)30323-5

N/A

0DataRank · unranked

76 citations

Heiko Schöder, Richard P. Baum, Ken Herrmann, Jonathan Strosberg, Martyn Caplin +3 more